Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.82 |
| ▸ | MAPT | P10636 | 7/20 | 0.82 |
| ▸ | NPC1 | O15118 | 5/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.65 |
| ▸ | RXRB | P28702 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11350421 | 1.00 | RAB9A (0.82) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL3729907 | 0.95 | NPC1 (0.75) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL12086470 | 0.95 | RAB9A (0.80) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL6959174 | 0.93 | NPC1 (0.73) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL898771 | 0.93 | RXRA (0.77) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL11363883 | 0.93 | RAB9A (0.73) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL255214 | 0.92 | NPC1 (0.71) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL254368 | 0.92 | NPC1 (0.71) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL18569721 | 0.92 | LOXL2 (0.75) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL6326840 | 0.92 | RAB9A (0.71) | RAB9AMAPTNPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | RAB9A 1106/4885MAPT 4328/4885NPC1 191/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | RAB9A 1106/4885MAPT 4328/4885NPC1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.